Dermata Therapeutics, Inc.
DRMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.26 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -35.01% | -448.04% | -347.39% | -1,387.93% |
| EV / EBITDA | -0.28 | 3.32 | 3.92 | 0.94 |
| Quality | ||||
| ROIC | -37.75% | -29.22% | -32.05% | -204.98% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 1.58 | 0.84 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 32.96% | -39.11% | 33.62% | 14.78% |
| Safety | ||||
| Net Debt / EBITDA | 2.65 | 3.66 | 4.15 | 1.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |